SINOPHARM GROUP CO News

WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.

① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?

cls.cn16:30

Sinopharm Group's Subsidiary Expects Up to 65% Lower Attributable Profit for 2024

MT Newswires14:57

Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.

In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.

Zhitong Finance13:51

Zhao Yin International: The Class B medical insurance catalog will be implemented within the year, Innovative Drugs will open up domestic payment space.

Zhao Yin International is Bullish on the valuation recovery of the Medical and Pharmaceutical Industry.

Zhitong Finance09:38

Sinopharm Group: Impairment on Goodwill, Other Assets Weighed on Results>1099.HK

Dow Jones07:04

Sinopharm Group Sees 2024 Net CNY561.0M-Net CNY760.0M >1099.HK

Dow Jones07:04

Sinopharm Group Expects 2024 Net to Fall Substantially >1099.HK

Dow Jones07:04

SINOPHARM (01099.HK) subsidiary China National Accord Medicines Corporation expects a full-year profit drop of over 52.5%.

SINOPHARM (01099.HK) announced that its subsidiary, China National Accord Medicines Corporation (000028.SZ), has issued a profit warning, expecting profits for the fiscal year 2024 to be between 0.561 billion and 0.76 billion yuan, a year-on-year decrease of 52.5%-64.9%. During the year, China National Accord Medicines Corporation plans to set aside an impairment reserve for goodwill and intangible assets of approximately 0.876 billion to 1.07 billion yuan, which will reduce net profit by 0.505 billion to 0.618 billion yuan.

AASTOCKSJan 19 22:03

SINOPHARM (01099): China National Accord Medicines Corporation (000028.SZ) expects a net profit attributable to the parent company of approximately 0.561 billion yuan to -0.76 billion yuan in 2024, a year-on-year decrease of 52.48% to 64.92%.

SINOPHARM (01099) announced that it is expected that China National Accord Medicines Corporation (000028.SZ) will belong to the...

Zhitong FinanceJan 19 18:55

SINOPHARM: INSIDE INFORMATION ANNOUNCEMENTRESULTS ESTIMATE OF SINOPHARM ACCORDFOR THE YEAR OF 2024

HKEXJan 19 18:47 · Announcements

Last year, the medical insurance Fund in the mainland was balanced with a slight surplus.

The press conference held by the National Medical Insurance Bureau stated that in 2024, the Medical Insurance Fund will balance its revenue and expenditure, with a slight surplus, ensuring the fund's safety and sustainability. According to preliminary aggregated data from the Medical Insurance Fund, in 2024, the total income of the national basic medical insurance fund will be 3.48 trillion yuan (RMB), an annual increase of 4.4%. The total expenditure of the national basic medical insurance fund will be 2.97 trillion yuan, an annual increase of 5.5%. The current surplus of the national medical insurance pooling fund is 470 billion yuan, with a cumulative balance of 3.87 trillion yuan. At the same time, the number of outpatient settlements in the national basic medical insurance has reached 6.7 billion visits, an annual increase of 19%. The maternity insurance fund is pending.

AASTOCKSJan 17 11:06

Express News | ICBC International has given SINOPHARM a buy rating for H Shares, with a Target Price of HKD 25.90.

BreakingsJan 14 19:06

National Medical Insurance Bureau: Expand payment channels for Innovative Drugs and guide benefit-oriented commercial health Insurance to include Innovative Drugs in the coverage responsibilities.

On January 9, 2024, the National Healthcare Security Administration held a symposium to support the development of Innovative Drugs, communicating with several pharmaceutical companies about the progress of Innovative Drugs and listening to their opinions and suggestions regarding support from the healthcare insurance department.

Zhitong FinanceJan 13 11:17

China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.

In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.

Zhitong FinanceJan 13 09:37

Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.

The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.

Zhitong FinanceJan 10 10:20

Sinopharm Group Announces Board of Directors and Committee Roles

TipRanksJan 8 21:37

SINOPHARM (01099.HK) plans to appoint Sun Jinglin as Executive Director.

Gelonghui, January 8: SINOPHARM (01099.HK) announced that on January 8, 2025, the Board of Directors resolved to recommend the appointment of Sun Jinglin as an executive director, and to recommend the appointment of Hu Ligang, Zu Jing, and Xing Yonggang as non-executive directors.

Gelonghui FinanceJan 8 21:21

China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk

WSJJan 7 16:23

Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.

Track the entire lifecycle of the main sector.

cls.cnJan 7 09:20

SINOPHARM (01099.HK) received a shareholding of 0.2396 million shares listed in Hong Kong from CITIC SEC Asset Management Co., Ltd. and related parties, valued at approximately 4.9962 million Hong Kong dollars.

On January 6, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 6, CITIC SEC Asset Management Co., Ltd. increased its shareholding in SINOPHARM (01099.HK) by 239,600 H-shares at an average price of HKD 20.8523 per share on January 3, with a total value of approximately HKD 4.9962 million. After the increase, CITIC SEC Asset Management Co., Ltd. now holds 0.121 billion shares, with the good warehouse percentage rising from 8.99% to 9.02%. This Trade involves Other related parties: CITIC SEC - Yunfan Single Asset Management Plan. Supplementary information: The equity is managed by CITIC SEC Asset Management Co., Ltd.

Futu NewsJan 6 17:04